arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Caribou Biosciences, Inc.

CRBU
$0.41 ▼ -0.03 (-7.02%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
28 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Caribou Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $41.4M
Dividend Yield —
Revenue Growth -43.8% ↘
Op. Margin None
ROIC -20.4% →
FCF / Share $-0.23 ↗
Trailing P/E —
Price / Book 0.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.50M
↓ -43.8% —
Net Income Profit after all expenses
$-25.09M
↑ +37.3% —
Operating Margin Operating profit as % of sales
-61.8%
↑ +86.8% —
FCF / Share Free cash flow per share
$-0.23
↑ +26.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
7
Cash Quality ↑
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 8 years · 28 quarters